Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Cleveland Clinic Taussig Cancer Institute

Z. Yetmar

Managing Women's Health in Menopause: Evolving Approaches for the Ma…

PleXus Communications

J. Simon, T. Iyer, A. Fiffick, M. Minkin

2024 Updates on Checkpoint Inhibitor Toxicities: A Nephrology Lens

Cleveland Clinic Taussig Cancer Institute

A. Mehdi

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents i…

2024 ESMO Annual Meeting Insights Hub

P. Garrido

How the Experts Manage: ADC-Associated Toxicities in NSCLC

MI&T Congressi

N. Leighl

Referral to Eye Care Provider for Management of Ocular Toxicity Asso…

Debra Richardson

WCLC 2024 Insights: Management of Radiation Toxicities in The Era of…

Insights from 2024 WCLC

P. Lee

Cutaneous Toxicity in Oncology: Mechanism and Management

OncoAlert

P. Bhargava

Pulmonary irAEs: Epidemiology, Diagnosis, and Treatment of ICI-P

Cleveland Clinic Taussig Cancer Institute

M. Smith

Management of Immunotherapy Related Side Effects in Melanoma

Melanoma Research Foundation

K. Gardner

Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrilla…

Lydia Scarfò

Strategies for Managing Toxicities of Oral Oncolytics in Lung Cancer…

UNC Lineberger Comprehensive Cancer Center

K. Chen, A. Faso, B. Patel

Pulmonary Complications of Checkpoint Inhibitor Therapy

Cleveland Clinic Taussig Cancer Institute

M. Smith